Villere ST Denis J & Co. LLC Cuts Holdings in OmniAb, Inc. (NASDAQ:OABI)

Villere ST Denis J & Co. LLC lowered its position in shares of OmniAb, Inc. (NASDAQ:OABI - Free Report) by 27.1% during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 1,499,315 shares of the company's stock after selling 556,472 shares during the quarter. Villere ST Denis J & Co. LLC owned 1.27% of OmniAb worth $6,342,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors also recently modified their holdings of OABI. Janus Henderson Group PLC boosted its position in OmniAb by 1.0% in the first quarter. Janus Henderson Group PLC now owns 7,859,438 shares of the company's stock worth $42,598,000 after purchasing an additional 81,541 shares during the last quarter. Vanguard Group Inc. boosted its holdings in shares of OmniAb by 1.1% in the 1st quarter. Vanguard Group Inc. now owns 5,713,539 shares of the company's stock worth $30,967,000 after buying an additional 62,131 shares during the last quarter. William Blair Investment Management LLC grew its position in OmniAb by 0.8% during the first quarter. William Blair Investment Management LLC now owns 3,364,346 shares of the company's stock valued at $18,235,000 after buying an additional 27,105 shares during the period. Dimensional Fund Advisors LP grew its position in OmniAb by 6.9% during the second quarter. Dimensional Fund Advisors LP now owns 3,012,216 shares of the company's stock valued at $11,296,000 after buying an additional 194,835 shares during the period. Finally, Rice Hall James & Associates LLC increased its holdings in OmniAb by 6.4% during the third quarter. Rice Hall James & Associates LLC now owns 2,722,321 shares of the company's stock worth $11,515,000 after buying an additional 163,038 shares during the last quarter. 72.08% of the stock is owned by institutional investors.

Analysts Set New Price Targets

OABI has been the subject of a number of research reports. HC Wainwright reissued a "buy" rating and set a $11.00 target price on shares of OmniAb in a research report on Monday, August 12th. Royal Bank of Canada reissued an "outperform" rating and issued a $7.00 target price on shares of OmniAb in a research report on Friday, August 16th. Finally, Benchmark reaffirmed a "buy" rating and set a $8.00 price target on shares of OmniAb in a research report on Monday, August 19th.

OmniAb Stock Down 0.2 %

OABI traded down $0.01 on Friday, hitting $4.52. The company's stock had a trading volume of 310,401 shares, compared to its average volume of 356,019. OmniAb, Inc. has a 12 month low of $3.56 and a 12 month high of $6.72. The firm has a market cap of $534.08 million, a P/E ratio of -7.29 and a beta of -0.12. The company's 50 day simple moving average is $4.17 and its 200-day simple moving average is $4.28.

OmniAb (NASDAQ:OABI - Get Free Report) last posted its earnings results on Thursday, August 8th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.18) by $0.05. The business had revenue of $7.61 million for the quarter, compared to analysts' expectations of $6.52 million. OmniAb had a negative net margin of 287.29% and a negative return on equity of 20.21%. During the same period in the prior year, the company posted ($0.15) EPS. Equities analysts predict that OmniAb, Inc. will post -0.58 earnings per share for the current fiscal year.

OmniAb Company Profile

OmniAb, Inc, a biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States. The company's technology platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts.